| HER2-Negative Breast Carcinoma studied in …STUDIED_INderived43 of 43show fewer |
|---|
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391774Phase 3 · recruiting Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179303Phase 2 · recruiting Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07085767Phase 3 · recruiting Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090398Phase 2 · active not recruiting Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03939897Phase 1 · active not recruiting Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06671912Phase 3 · suspended Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016738Phase 3 · active not recruiting OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06525766Phase 2 · recruiting Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176261Phase 2 · recruiting DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052555Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026657Phase 1/Phase 2 · recruiting Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05098210Phase 1 · recruiting Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464810early Phase 1 · recruiting Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05677802NA · recruiting Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06008158Phase 2 · active not recruiting Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07136493NA · withdrawn Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05770531Phase 2 · recruiting Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07483307Phase 2 · recruiting A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06388122recruiting DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06678269Phase 1 · recruiting A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647916Phase 2 · active not recruiting Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276880Phase 2 · recruiting Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05488145NA · terminated A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06042569Phase 2 · recruiting Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07112053Phase 2 · recruiting A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06450873Phase 2 · recruiting Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554354Phase 2 · terminated Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02157051Phase 1 · active not recruiting Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04150042Phase 1 · recruiting SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04481113Phase 1 · completed Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer · condition mapped ALIAS · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06534125NA · recruiting Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06774027recruiting Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572800NA · completed Tka Assay for CDK4/6i · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04379570Phase 3 · active not recruiting Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy · condition mapped ONTOLOGY_EXACT · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06590558Phase 1 · withdrawn Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05535413Phase 1/Phase 2 · recruiting UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05967286Phase 2 · withdrawn Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04756505Phase 1 · withdrawn Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05085626Phase 2 · unknown Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05244434NA · withdrawn Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04498520Phase 1 · withdrawn Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer · condition mapped CURATED_BROADER · 43 trials mapped (31 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |